And the crossing of survival curves between anti-PDL1 and chemotherapy in the phase 3 KEYNOTE-061 and KEYNOTE-062 trials also suggested a period needed for awakening the immune system to attack tumor cells after the initiation of ICIs (7, 8), addressing the importance of immunological background in driving and sustaining efficacious immunotherapy responses. This evidence concerns the gene CD274 and neoplasm.